How inflammation changes blood stem cells and drives progression in chronic myelomonocytic leukemia
Official title: The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-11285307 · Data updated 2026-11-12
Looking at whether inflammation changes blood stem cells and speeds disease in adults with CMML.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | March 7, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2026 |
| Award (this year) | $495,033 |
| NIH project number | 5R01CA278300-04 |
| Project ID | NIH-11285307 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults diagnosed with CMML who can provide blood and/or bone marrow samples and agree to clinical follow-up are the ideal candidates.
✕Less likely to help
People without CMML, those already in frank AML, or individuals unwilling to give samples or attend follow-up visits are unlikely to benefit directly.
What this research studies
As someone with CMML, this project will examine how inflammation alters the mix of blood stem and progenitor cells in your bone marrow and blood. Researchers will analyze patient blood and bone marrow samples over time and compare molecular patterns in people who progress to AML versus those who remain stable. They will also use laboratory models that mimic inflammation to see if inflammatory programs make certain leukemia stem cells more competitive. Findings will be linked to clinical outcomes to help identify markers or targets to slow progression.
Why it matters
Potential benefit: If successful, this could identify inflammatory markers or pathways that predict or slow CMML progression and reduce the chance of transformation to AML.
How similar studies have gone: Preliminary lab work and a retrospective patient cohort suggest inflammatory shifts in progenitor cells are linked to worse outcomes, but translating this into clinical markers and therapies is still new.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Padron, Eric — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Padron, Eric
Related research
Other NIH-funded projects on the same topics.
-
Targeted therapies for a blood cancer called CMML (CBL-mutant CMML)
A physician-scientist is testing targeted drugs to treat a hard-to-kill blood cancer called CMML in patients whose cancer has CBL mutations.
-
Understanding how CMML develops and becomes aggressive
Looks at blocking overactive MEK/ERK signals and BET protein-driven gene activity to slow or reverse aggressive CMML and lower its chance of turning into AML for people whose leukemia has NRAS and ASXL1 mutations.
-
Blocking PLK1 in RAS‑mutated chronic myelomonocytic leukemia
People with relapsed or refractory proliferative CMML that has RAS pathway mutations will receive an oral drug called onvansertib that blocks the cell‑division protein PLK1 to look for safety and early signs of benefit.
-
Patient-based mouse models to find better treatments for chronic myelomonocytic leukemia
Researchers are using mice implanted with patients' CMML cells to try out new treatment approaches for people with chronic myelomonocytic leukemia.
-
Understanding how chronic myelomonocytic leukemia resists targeted therapy
This study is looking at how some people with chronic myelomonocytic leukemia (CMML) might not respond to a treatment called cobimetinib, and it aims to help those patients by figuring out why that happens and finding better ways to treat them.
-
Targeting a specific protein to treat a type of blood cancer
This study is looking at a new pill called Onvansertib to see if it can help people with a tough type of blood cancer called chronic myelomonocytic leukemia (CMML) that hasn't responded to other treatments, especially for those with specific gene changes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.